NICE recommends cladribine for treating active relapsing forms of multiple sclerosis

The National Institute for Health and Care Excellence (NICE) has expanded access to cladribine (Mavenclad; Merck) for adults with active relapsing-remitting multiple sclerosis (MS), if they would otherwise be offered highly effective disease-modifying drugs. The technology appraisal guidance, published on 15 April 2025, said that cladribine can be offered to people with MS as an alternative to Ocrevus […]

Publication Details

Journal: Pharmaceutical journal/The pharmaceutical journal
Published: 2025-01-01
DOI: https://doi.org/10.1211/pj.2025.1.353908
Primary Topic: Chronic Lymphocytic Leukemia Research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

NICE recommends cladribine for treating active relapsing forms of multiple sclerosis

Jan 1, 2025

2 links

Pharmaceutical journal/The pharmaceutical journal

Chronic Lymphocytic Leukemia Research

article

NICE recommends cladribine for treating active relapsing forms of multiple sclerosis

January 1, 2025article en

Abstract

Pharmaceutical journal/The pharmaceutical journal

Openalex Percentile: Top 89%

Chronic Lymphocytic Leukemia Research

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

NICE recommends cladribine for treating active relapsing forms of multiple sclerosis · Pharmaceutical journal/The pharmaceutical journal (2025) | TGRS Research Map | TGRS